NEFL and Alzheimer disease: HTT appears to act differently in patients with other biomarker profiles (isolated Aβ pathology or non-AD), as the number of CAG repeats was associated with lower metabolism in frontal regions but had no effect on plasma NfL concentration neither on brain metabolism.